Versigent Has Already Run, But I Still See More Upside

Sam Mancini 1 Follower Follow Summary Versigent delivered a strong first full quarter as an independent company, with sales up 10.8 percent and adjusted EBITDA up 24.8 percent. The stock is not as cheap as it was right after the Aptiv separation, but a valuation near 5.1 times expected 2026 adjusted EBITDA still looks reasonable. Debt and weak first-half cash conversion are the two issues I am watching most closely. I rate VGNT a Buy and value the shares at $58, about 24 percent above the current price. Editor's note: Seeking Alpha is proud to welcome Sam Mancini as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. This article was written by Sam Mancini 1 Follower Follow Hey this is Sam, an independent investor with a degree in Finance from the University of Oklahoma. I have been investing my own money for several years, with a focus on finding companies that may be overlooked, misunderstood, or valued too conservatively by the market.I am most interested in small and mid sized companies with strong growth potential, especially within technology, artificial intelligence, financial technology, aerospace, and digital infrastructure. I am drawn to businesses operating in growing markets. I also look outside these areas when I find a company with a compelling valuation or an overlooked catalyst.My investing approach combines fundamental research with valuation, market sentiment, and technical analysis. I review financial statements, earnings reports, investor presentations, management commentary, industry trends, and competitive positioning before forming a thesis. I pay particular attention to revenue growth, margins, balance sheet strength, dilution risk, and whether current expectations already appear reflected in the share price.I write independently and am not affiliated with an investment firm. I joined Seeking Alpha to share research on companies that I believe deserve a closer look. My goal is to present a clear investment case, explain what could drive the stock higher, and address the risks that could prove the thesis wrong. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.